Optical Genome Mapping is a new genome-wide, high-resolution assay for structural, chromosomal variation (i.e. structural and numeric changes). Its use is growing in Canada and around the world, especially in hematologic malignancies. With the higher resolution offered by OGM, we will see improved genetic classification for patients, and likely also an increase in novel observations.
Evolving Role of FLT3 Analysis in AML Diagnosis and Management: Presentation and Discussion When: Monday, June 19, 2023, 7:00 PM EST Where: Zoom – link will be provided upon registration Faculty : Kristjan Paulson CancerCare Manitoba Department of Medicine
Evolving Role of FLT3 Analysis in AML Diagnosis and Management: Presentation and Discussion When: Monday, May 29, 2023, 7:00 PM EST Where: Zoom – link will be provided upon registration Faculty : Julie Bergeron, MD Hôpital Maisonneuve-Rosemont, Montreal, QC José-Mario Capo-Chichi, PhD University Health Network, Toronto, ON Hubert Tsui, MD Sunnybrook Health Sciences Centre, Toronto, ON Questions […]
While maintenance therapy has long been a standard of care in ALL and in APL, until recently there has been little evidence to support its use in non-APL AML. In this webinar we will review recent data that have led to the approval of oral azacitidine for AML maintenance, will define the optimal use of oral azacitidine for this indication, and will discuss the evolving role of maintenance therapy in FLT3-mutated AML.
Discuss how to deal with confusion around conflicting AML classification systems.
The first Annual General Meeting (AGM) of the Canadian Leukemia Study Group is being held in January and we would like to share the proceedings with you.
The purpose of the Pharmacy Interest Group groups is to address the specific needs of Acute Leukemia Pharmacy practice, within the mandate of CLSG, which in brief, is to improve Acute Leukemia care in Canada.
The first Annual General Meeting (AGM) of the Canadian Leukemia Study Group/Groupe Canadien D’Étude Sur La Leucémie will be held on Monday, January 24, 2022 from 5:30 - 7:30 PM EST
The founding goals of CLSG are to advance the diagnosis and treatment of leukemia in Canada, by identifying diagnostic and management best practices, promoting Canada-wide standards-of-care, fostering clinical and basic leukemia research, and improving new drug access.
The founding goals of CLSG are to advance the diagnosis and treatment of leukemia in Canada, by identifying diagnostic and management best practices, promoting Canada-wide standards-of-care, fostering clinical and basic leukemia research, and improving new drug access.
The founding goals of CLSG are to advance the diagnosis and treatment of leukemia in Canada, by identifying diagnostic and management best practices, promoting Canada-wide standards-of-care, fostering clinical and basic leukemia research, and improving new drug access.